SLC5A2 and chronic kidney disease: SGLT2 inhibitors have demonstrated significant renoprotective effects in patients with type 2 diabetes and CKD, reducing the risk of renal disease progression, the need for dialysis or kidney transplantation, and renal or cardiovascular mortality.